{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:30:51Z","timestamp":1794850251293,"version":"4.9.1"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","annemergmed.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.annemergmed.2024.10.015","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:13:06Z","timestamp":1733267586000},"page":"214-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1163-3724","authenticated-orcid":false,"given":"Danna Michelle","family":"Markides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Guido","family":"Hita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cielto","family":"Reyes-Gibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-ching J.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2024.10.015_bib1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib128","series-title":"Cytotoxic Payloads for Antibody-Drug Conjugates","first-page":"1","article-title":"Introduction to Antibody-drug conjugates","author":"Pysz","year":"2019"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib129","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib50","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib131","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib132","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib87","series-title":"Besponsa (inotuzumab ozogamicin) [package insert]","year":"2024"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib90","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib133","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00277-021-04711-9","article-title":"Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience","volume":"101","author":"Wang","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib74","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib78","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib71","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib92","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase ii open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib134","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib43","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib119","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib136","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib137","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/fon-2017-0646","article-title":"FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib139","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14740338.2014.893293","article-title":"Safety and efficacy evaluation of albumin-bound paclitaxel","volume":"13","author":"Cecco","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib141","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/ajhp\/54.suppl_2.S19","article-title":"Efficacy and safety of docetaxel in clinical trials","volume":"54","author":"Fumoleau","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib142","unstructured":"Micromedex. Brentuximab Vedotin: Merative."},{"key":"10.1016\/j.annemergmed.2024.10.015_bib143","series-title":"Adcetris (brentuximab vedotin) [package insert]","year":"2023"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib7","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib146","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib79","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib91","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib155","series-title":"Merative","year":"2024"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis","volume":"184","author":"Zhu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib6","series-title":"Elahere [package insert]","author":"ImmunoGen","year":"2022"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2022.07.014","article-title":"Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure","volume":"174","author":"Yoon","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12185-020-03039-w","article-title":"Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study","volume":"113","author":"Izutsu","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/17425255.2022.2162383","article-title":"Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore","volume":"18","author":"Yong","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib12","series-title":"Tivdak[package insert]","author":"Seagan","year":"2022"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the european society for blood and marrow transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib18","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib21","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.3390\/ijms24065620","article-title":"Molecular advances in sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"24","author":"Mavrikou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib159","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.clineuro.2012.03.019","article-title":"Brentuximab associated progressive multifocal leukoencephalopathy","volume":"114","author":"Jalan","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"53","author":"Wagner-Johnston","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib25","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib26","article-title":"Treatment strategies to optimize outcomes with brentuximab vedotin: management of common and rare toxicities","volume":"4","author":"Fanale","year":"2015","journal-title":"J\u00a0Target Ther Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ncl.2018.06.002","article-title":"Progressive multifocal leukoencephalopathy","volume":"36","author":"Grebenciucova","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib28","article-title":"The clinical features of progressive multifocal leukoencephalopathy","volume":"78","author":"Berger","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib29","article-title":"PRES-like leukoencephalopathy presenting with status epilepticus associated with Brentuximab Vedotin treatment","volume":"92","author":"Orsini","year":"2022","journal-title":"Acta Biomed"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"Fargeot","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/CAD.0000000000001117","article-title":"Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report","volume":"32","author":"Papageorgiou","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5348\/OCY-2014-6-RA-2","article-title":"Infusion reactions associated with use of biologic medicines in cancer therapy","volume":"4","author":"Singh","year":"2014","journal-title":"Oncocytology"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib34","first-page":"190","article-title":"Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory hodgkin lymphoma patients","volume":"34","author":"Uncu Ulu","year":"2022","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Pond\u00e9","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib40","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/17512433.2022.2121704","article-title":"Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials","volume":"15","author":"Liu","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib41","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib42","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1097\/MPH.0000000000002325","article-title":"Acute left ventricular dysfunction following gemtuzumab ozogamicin in two pediatric AML patients","volume":"44","author":"McNerney","year":"2022","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib44","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib45","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib46","series-title":"Mylotarg (gemtuzumab ozogamicin). [Package insert]","year":"2021"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib48","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib49","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","article-title":"Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib51","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury. Trastuzumab Emtansine. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. [Internet]. 2012. [Updated 2024 Jan 30]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK600083\/"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib52","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1080\/10428194.2019.1579321","article-title":"Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy","volume":"60","author":"Neeman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib53","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury. Brentuximab Vedotin. [Internet] 2012. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012. [Updated 2024 Jan 10]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548802\/"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib54","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","article-title":"A\u00a0pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib59","series-title":"Polivy (polatuzumabvedotin-piiq) [package insert]","year":"2023"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib60","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Enfortumab Vedotin. [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Internet]. 2012. [Updated 2023 Nov 30]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK598876\/."},{"key":"10.1016\/j.annemergmed.2024.10.015_bib61","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tisotumab Vedotin. [Internet]. 2012. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Updated 2023 Nov 30]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK598988\/."},{"key":"10.1016\/j.annemergmed.2024.10.015_bib62","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Sacituzumab Govitecan. [Internet]. 2012. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Updated 2023 Nov 30].https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK598987\/."},{"key":"10.1016\/j.annemergmed.2024.10.015_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroentero"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib64","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Gemtuzumab Ozogamicin. [Internet]. 2012. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Updated 2023 Nov 30]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548438\/"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib65","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Trastuzumab Deruxtecan","year":"2024"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib66","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Polatuzumab Vedotin. [Internet]. 2012. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Updated 2023 Nov 30]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK598989\/"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib67","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib68","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib69","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib70","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib72","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib76","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib81","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib83","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib84","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3109\/0284186X.2014.920959","article-title":"Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage","volume":"53","author":"Kolarich","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12885-016-2464-1","article-title":"Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases","volume":"16","author":"Mitsuya","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.wneu.2017.12.072","article-title":"Progressively enlarging cerebellar hematoma concurrent with T-DM1 treatment","volume":"111","author":"Vilela","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib88","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50423","article-title":"Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US","volume":"6","author":"Alishahi Tabriz","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib89","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib93","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10637-019-00768-6","article-title":"A\u00a0phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","volume":"37","author":"Sharman","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib161","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib94","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1080\/10428194.2022.2045601","article-title":"Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study","volume":"63","author":"Moore","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-014-0036-x","article-title":"Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report","volume":"14","author":"Urru","year":"2014","journal-title":"Drugs R D"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib96","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610445","article-title":"Case report: brentuximab vedotin associated acute pancreatitis in a pediatric hodgkin lymphoma patient: case report and literature review","volume":"28","author":"Truszkowska","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib98","first-page":"e5138","article-title":"Hypertriglyceridemia induced pancreatitis due to brentuximab therapy: first case report","volume":"11","author":"Maradana","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib99","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5811\/westjem.2018.12.37335","article-title":"Diagnosis and management of oncologic emergencies","volume":"20","author":"Klemencic","year":"2019","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib100","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib102","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib104","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib105","first-page":"12","article-title":"Uveitis induced by brentuximab vedotin-A novel adverse response to antibody- drug conjugate therapy","volume":"4","author":"Antman","year":"2021","journal-title":"Clin Oncol Case Rep"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/10428194.2021.1978090","article-title":"Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate","volume":"63","author":"Costa","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib107","article-title":"Brentuximab vedotin induced uveitis","volume":"26","author":"Therssen","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib162","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib113","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-Positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib163","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A\u00a0phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0301-4738.58471","article-title":"Current approach in the diagnosis and management of panuveitis","volume":"58","author":"Bansal","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib109","article-title":"Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology","volume":"46","author":"Richardson","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib110","doi-asserted-by":"crossref","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib111","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib112","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00277-014-2148-3","article-title":"Extensive toxic epidermal necrolysis following brentuximab vedotin administration","volume":"94","author":"Del Principe","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib114","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00277-015-2538-1","article-title":"Brentuximab-induced hand-foot syndrome in a Hodgkin lymphoma patient","volume":"95","author":"Rehman","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib116","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1590\/abd1806-4841.20187968","article-title":"Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment","volume":"93","author":"Ruiz-Rivero","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10549-014-3001-z","article-title":"Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series","volume":"146","author":"Sibaud","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib118","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.chest.2015.09.008","article-title":"Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report","volume":"149","author":"Kwon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib120","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1177\/10781552211015772","article-title":"Trastuzumab-emtansine induced pleural and pericardial effusions","volume":"27","author":"Lombardi","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib121","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.urolonc.2022.07.006","article-title":"Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: a scoping review","volume":"40","author":"Padua","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib123","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib124","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.2147\/OTT.S193951","article-title":"Safety and efficacy of brentuximab vedotin in the treatment of classic hodgkin lymphoma","volume":"13","author":"Makita","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib125","article-title":"Diabetic ketoacidosis and profound insulin resistance from brentuximab vedotin","volume":"15","author":"Thakkar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s13410-022-01116-w","article-title":"Brentuximab vedotin-associated diabetic ketoacidosis: a case report","volume":"43","author":"K\u00f6ksalan","year":"2023","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.annemergmed.2024.10.015_bib127","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064424011429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064424011429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:36:42Z","timestamp":1740418602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064424011429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0196064424011429"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.10.015","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}